Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 1
1978 1
1979 2
1980 2
1981 2
1982 1
1984 1
1985 1
1986 1
1989 2
1992 1
1994 1
1995 2
1998 6
2000 3
2001 3
2002 2
2003 2
2004 4
2005 5
2006 6
2007 9
2008 9
2009 11
2010 8
2011 8
2012 13
2013 17
2014 17
2015 24
2016 24
2017 27
2018 32
2019 35
2020 59
2021 103
2022 126
2023 159
2024 50

Text availability

Article attribute

Article type

Publication date

Search Results

696 results

Results by year

Filters applied: . Clear all
Page 1
Tumor aerobic glycolysis confers immune evasion through modulating sensitivity to T cell-mediated bystander killing via TNF-α.
Wu L, Jin Y, Zhao X, Tang K, Zhao Y, Tong L, Yu X, Xiong K, Luo C, Zhu J, Wang F, Zeng Z, Pan D. Wu L, et al. Cell Metab. 2023 Sep 5;35(9):1580-1596.e9. doi: 10.1016/j.cmet.2023.07.001. Epub 2023 Jul 27. Cell Metab. 2023. PMID: 37506695
Genetic and pharmacological inactivation of Glut1 sensitizes tumors to anti-tumor immunity and synergizes with anti-PD-1 therapy through the TNF-alpha pathway. The mechanistic interplay between tumor-intrinsic glycolysis and TNF-alpha-induced killing provides new th …
Genetic and pharmacological inactivation of Glut1 sensitizes tumors to anti-tumor immunity and synergizes with anti-PD-1 thera …
Exosomes in cancer development, metastasis, and immunity.
Zhang L, Yu D. Zhang L, et al. Biochim Biophys Acta Rev Cancer. 2019 Apr;1871(2):455-468. doi: 10.1016/j.bbcan.2019.04.004. Epub 2019 Apr 30. Biochim Biophys Acta Rev Cancer. 2019. PMID: 31047959 Free PMC article. Review.
In this review, we summarize the functions of exosomes in cancer development, metastasis, and anti-tumor or pro-tumor immunity, plus their application in cancer treatment and diagnosis/prognosis. ...
In this review, we summarize the functions of exosomes in cancer development, metastasis, and anti-tumor or pro-tumor immunity …
GPC2 Is a Potential Diagnostic, Immunological, and Prognostic Biomarker in Pan-Cancer.
Chen G, Luo D, Zhong N, Li D, Zheng J, Liao H, Li Z, Lin X, Chen Q, Zhang C, Lu Y, Chan YT, Ren Q, Wang N, Feng Y. Chen G, et al. Front Immunol. 2022 Mar 8;13:857308. doi: 10.3389/fimmu.2022.857308. eCollection 2022. Front Immunol. 2022. PMID: 35345673 Free PMC article.
The expression level of GPC2 in a variety of tumors is significantly different from that of normal tissues. In addition, the performance of GPC2 in tumorigenesis and tumor immunity also confirms our conjecture. At the same time, it has high specificity and sensitivi …
The expression level of GPC2 in a variety of tumors is significantly different from that of normal tissues. In addition, the performance of …
Hepatocellular Carcinoma Immune Landscape and the Potential of Immunotherapies.
Giraud J, Chalopin D, Blanc JF, Saleh M. Giraud J, et al. Front Immunol. 2021 Mar 18;12:655697. doi: 10.3389/fimmu.2021.655697. eCollection 2021. Front Immunol. 2021. PMID: 33815418 Free PMC article. Review.
We describe the molecular and immunological classifications of HCC, discuss the role of specific immune cell subsets in this cancer, with a focus on myeloid cells and pathways in anti-tumor immunity, tumor promotion and immune evasion. We also describe the challenge …
We describe the molecular and immunological classifications of HCC, discuss the role of specific immune cell subsets in this cancer, with a …
Exosomal circRNA: emerging insights into cancer progression and clinical application potential.
Zhang F, Jiang J, Qian H, Yan Y, Xu W. Zhang F, et al. J Hematol Oncol. 2023 Jun 26;16(1):67. doi: 10.1186/s13045-023-01452-2. J Hematol Oncol. 2023. PMID: 37365670 Free PMC article. Review.
In this review, we summarize the functions and underlying mechanisms of tumor cell and non-tumor cell-derived exosomal circRNAs in cancer progression, with a special focus on their roles in tumor immunity and metabolism. Finally, we examine the potential application …
In this review, we summarize the functions and underlying mechanisms of tumor cell and non-tumor cell-derived exosomal circRNAs in cancer pr …
Base editing screens map mutations affecting interferon-γ signaling in cancer.
Coelho MA, Cooper S, Strauss ME, Karakoc E, Bhosle S, Gonçalves E, Picco G, Burgold T, Cattaneo CM, Veninga V, Consonni S, Dinçer C, Vieira SF, Gibson F, Barthorpe S, Hardy C, Rein J, Thomas M, Marioni J, Voest EE, Bassett A, Garnett MJ. Coelho MA, et al. Cancer Cell. 2023 Feb 13;41(2):288-303.e6. doi: 10.1016/j.ccell.2022.12.009. Epub 2023 Jan 19. Cancer Cell. 2023. PMID: 36669486 Free PMC article.
Interferon-gamma (IFN-gamma) signaling mediates host responses to infection, inflammation and anti-tumor immunity. Mutations in the IFN-gamma signaling pathway cause immunological disorders, hematological malignancies, and resistance to immune checkpoint blockade (I …
Interferon-gamma (IFN-gamma) signaling mediates host responses to infection, inflammation and anti-tumor immunity. Mutations i …
Signal pathways and precision therapy of small-cell lung cancer.
Yuan M, Zhao Y, Arkenau HT, Lao T, Chu L, Xu Q. Yuan M, et al. Signal Transduct Target Ther. 2022 Jun 15;7(1):187. doi: 10.1038/s41392-022-01013-y. Signal Transduct Target Ther. 2022. PMID: 35705538 Free PMC article. Review.
Currently, there are six types of potential treatable signaling pathways in SCLC, including signaling pathways targeting the cell cycle and DNA repair, tumor development, cell metabolism, epigenetic regulation, tumor immunity and angiogenesis. At this point, however …
Currently, there are six types of potential treatable signaling pathways in SCLC, including signaling pathways targeting the cell cycle and …
Effect of exosomal miRNA on cancer biology and clinical applications.
Sun Z, Shi K, Yang S, Liu J, Zhou Q, Wang G, Song J, Li Z, Zhang Z, Yuan W. Sun Z, et al. Mol Cancer. 2018 Oct 11;17(1):147. doi: 10.1186/s12943-018-0897-7. Mol Cancer. 2018. PMID: 30309355 Free PMC article. Review.
After release, exosomes are taken up by neighboring or distant cells, and the miRNAs contained within modulate such processes as interfering with tumor immunity and the microenvironment, possibly facilitating tumor growth, invasion, metastasis, angiogenesis and drug …
After release, exosomes are taken up by neighboring or distant cells, and the miRNAs contained within modulate such processes as interfering …
CircPVT1 promotes ER-positive breast tumorigenesis and drug resistance by targeting ESR1 and MAVS.
Yi J, Wang L, Hu GS, Zhang YY, Du J, Ding JC, Ji X, Shen HF, Huang HH, Ye F, Liu W. Yi J, et al. EMBO J. 2023 May 15;42(10):e112408. doi: 10.15252/embj.2022112408. Epub 2023 Apr 3. EMBO J. 2023. PMID: 37009655 Free PMC article.
Furthermore, circPVT1 directly interacts with MAVS protein to disrupt the RIGI-MAVS complex formation, inhibiting type I interferon (IFN) signaling pathway and anti-tumor immunity. Anti-sense oligonucleotide (ASO)-targeting circPVT1 inhibits ERalpha-positive breast …
Furthermore, circPVT1 directly interacts with MAVS protein to disrupt the RIGI-MAVS complex formation, inhibiting type I interferon (IFN) si …
696 results